Our goal is to discover and develop cures for patients diagnosed with rare cancers. We focus on areas of high, unmet need: rare cancer indications with high mortality rates and few therapeutic options beyond resection and radiation. We strive to match each biological target with the optimal technology platform in order to develop a life-saving therapeutic specifically for that indication.
SHEPHERD’s approach prioritizes the convergence of life science, social science, and computation. SHEPHERD uses a proprietary software, that combines deep learning artificial intelligence and proprietary algorithms with traditional quantitative and qualitative statistical analysis. We start by mapping the mutational landscape (every known target and pathway) of every rare cancer, then add in significant qualitative variables related to patient profile, environmental data, and demographics to inform the best treatment modality. Our ability to identify target overlap, combined with our deep knowledge of each cancer, allows us to engineer an optimal therapeutic combination and delivery technology for multiple rare cancers.
Projects in our pipeline are currently in the preclinical phase of development. External collaborations and opportunities are also being pursued with the National Cancer Institute and the Massachusetts Institute of Technology.